The Roche (ROG: SIX) majority-owned drugmaker Chugai (TYO: 4519) has settled with the UK Research and Innovation agency and associated charity LifeArc, nearly three years after the lawsuit was filed against the company.
An undisclosed sum will be paid by Chugai to end the dispute, which began with the research groups making a claim on May 10, 2017, that the company had breached its obligations under a collaboration agreement dated August 15, 1990, in connection with the development of the humanized anti-human interleukin (IL)-6 receptor monoclonal antibody, Actemra (tocilizumab).
Actemra is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze